Palatin Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Palatin Technologies (PTN) reported a fiscal first-quarter 2027 net loss of $5,057,511 while advancing its experimental obesity drug programs. Revenue for the quarter ended September 30, 2026 fell to $361,802 from $8,847,550 a year earlier, when revenue included upfront and milestone payments. The prior-year quarter generated net income of $4,677,534. Cash declined to $3,740,424 from $7,492,014 at June 30, 2026. Additional funding is required, and substantial doubt exists about continued operations for one year following issuance of the financial statements.
Palatin targets a first human study of its long-acting MC4R peptide in the first half of 2027, with initial data in the second half. Its oral small-molecule study is targeted for the second half of 2027, with initial data in the first half of 2028. Studies needed before human testing and manufacturing activities are ongoing for the peptide.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Boehringer Ingelheim collaboration reimburses approved research costs and provides potential milestones and tiered royalties if products commercialize.
- Moderate pointPL9643 sublicense assigns future development and commercialization to Altanispac; Palatin remains eligible for additional payments and tiered royalties.
- Minor point. Forward-looking: it has not happened yet and may not happen.Long-acting peptide Phase 1 initiation targeted for first-half 2027; initial data targeted for second-half 2027.
- Minor pointPL2000 peptide reduced food intake and body weight with once-weekly injections in an obese mouse model.
- Minor pointTested peptide compounds activated MC4R without MC1R agonism, supporting Palatin's goal of reducing treatment-related skin darkening.
6 minor points
- Minor pointPL1000 development continues, including controlled-release formulations as another approach to long-acting therapy.
- Minor pointOral small-molecule candidates showed improved potency and MC4R selectivity versus earlier compounds in preclinical studies.
- Minor point. Forward-looking: it has not happened yet and may not happen.Oral program targets pre-human-testing development in first-half 2027 and Phase 1 initiation in second-half 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.Oral small-molecule initial clinical data targeted for the first half of 2028.
- Minor pointOral peptide agonist approach is also being explored to expand the development portfolio.
- Minor pointPartnering opportunities remain under evaluation for bremelanotide in obesity, ulcerative colitis assets and the diabetic nephropathy program.
Negative
- Major pointAdditional funding is required; substantial going-concern doubt covers one year following issuance of the financial statements.
- Major pointNet result shifted to a $5,057,511 loss from $4,677,534 income in the prior-year quarter.
- Moderate pointQuarterly revenue fell to $361,802 from $8,847,550; the prior-year period included upfront and milestone revenue.
- Moderate pointOperating cash use increased to approximately $3.7 million from approximately $1.6 million in the prior-year quarter.
- Moderate pointCash and equivalents declined to $3,740,424 at September 30, 2026, from $7,492,014 at June 30, 2026.
- Moderate pointR&D expense rose to $3,383,743 from $2,525,766; MC4R obesity spending increased to approximately $2.1 million from approximately $1.0 million.
- Moderate pointWorking capital declined to $1,780,825 at September 30, 2026, from $6,392,514 at June 30, 2026.
4 minor points
- Minor pointBasic/diluted loss per share was $1.29, versus prior-year basic/diluted earnings of $4.81/$4.26.
- Minor pointGeneral and administrative expense rose to $2,080,414 from $1,660,731, reflecting higher stock-based compensation and professional fees.
- Minor pointStockholders' equity declined to $2,026,079 at September 30, 2026, from $6,686,465 at June 30, 2026.
- Minor pointTotal liabilities increased to $2,692,098 at September 30, 2026, from $1,837,389 at June 30, 2026.
News Explained
Palatin said additional funding is required; its cash balance at
Sources and calculations
- Palatin fiscal first-quarter 2027 results and business update (2026-11-17)
- Palatin 2027Q1 fundamentals (2026-09-30)
- Available liquidity against the last reported quarterly operating outflow, in days at that rate $3,740,424 / ($3,741,589 / 92) = 92 days
Key Figures
- Collaboration and license revenue
- Approximately $0.4 million vs. approximately $8.8 million
- Fiscal Q1 2027 vs. comparable prior-year period
- MC4R obesity program R&D
- Approximately $2.1 million vs. approximately $1.0 million
- Fiscal Q1 2027 vs. comparable prior-year period
- Net loss
- Approximately $5.1 million
- Fiscal Q1 2027
- Net cash used in operating activities
- Approximately $3.7 million vs. approximately $1.6 million
- Fiscal Q1 2027 vs. comparable prior-year period
- Cash and cash equivalents
- Approximately $3.7 million vs. approximately $7.5 million
- September 30, 2026 vs. June 30, 2026
- Going-concern assessment
- One year following issuance of the financial statements
- Substantial doubt stated about the company’s ability to continue as a going concern
- Long-acting peptide Phase 1
- Initiation targeted for the first half of calendar 2027; initial data targeted for the second half of 2027
- MC4R-selective peptide program
- Oral small-molecule Phase 1
- Initiation targeted for the second half of calendar 2027; initial data targeted for the first half of 2028
- MC4R-selective oral program
Previous Earnings Reports
-
Reported $7.5 million cash and said additional financing was needed to support development.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
mc4r medical
mc1r medical
pharmacokinetic medical
ind-enabling regulatory
cmc technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Advancing differentiated next-generation MC4R agonists toward first-in-human clinical studies in 2027
- Lead lipidated, long-acting MC4R-selective peptide advancing through IND-enabling and manufacturing activities, with Phase 1 initiation targeted for the first half of calendar 2027
- Preclinical findings demonstrate selective and potent MC4R agonism with minimal to no MC1R activity in tested peptide compounds, supporting the potential to substantially reduce or eliminate MC1R-mediated hyperpigmentation
- Expanding oral MC4R opportunities through next-generation small-molecule development and an oral peptide agonist approach
- Oral small-molecule MC4R-selective agonist Phase 1 study targeted for the second half of calendar 2027
- First-quarter R&D investment in MC4R obesity programs more than doubled year over year, reflecting advancement of key preclinical development activities
- Conference call and webcast scheduled for November 17, 2026 at 11:00 a.m. ET
"MC4R agonism is now a clinically and commercially validated therapeutic approach for rare neuroendocrine obesity disorders, and we believe the next generation of therapies will be defined not only by efficacy, but by meaningful improvements in tolerability, convenience and long-term usability," said Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies. "Our development strategy is specifically designed to address these challenges. We are building on more than two decades of melanocortin research and drug development experience to advance highly selective MC4R agonists with the potential to deliver robust efficacy while substantially reducing, and potentially eliminating, MC1R-mediated hyperpigmentation."
"Our lead lipidated peptide program represents a particularly compelling opportunity," continued Dr. Spana. "We have demonstrated significant efficacy with once-weekly dosing in preclinical models, and pharmacokinetic findings support the potential for once-weekly or less frequent administration in humans. Equally important, tested compounds in our next-generation peptide series have demonstrated potent MC4R activation without meaningful MC1R activation, an important attribute for developing therapies with improved long-term tolerability. We believe this combination of selectivity, efficacy and sustained activity provides a strong foundation for developing a differentiated therapy for patients who require lifelong treatment."
"During the quarter, we continued to advance IND-enabling activities with our long-acting peptide while progressing our next-generation oral small-molecule candidates and additionally exploring oral peptide opportunities. We are targeting the initiation of our first Phase 1 study in the first half of 2027, followed by our oral small-molecule program in the second half of 2027. We believe these programs have the potential to establish a new standard for MC4R-targeted treatment of rare obesity disorders."
MC4R Obesity Program Update
Palatin is advancing a portfolio of MC4R-selective agonists designed to address hypothalamic obesity ("HO"), Prader-Willi syndrome ("PWS"), Bardet-Biedl syndrome ("BBS") and other rare obesity disorders associated with dysfunction of the melanocortin pathway.
The Company's strategy focuses on developing therapies with meaningful efficacy, improved gastrointestinal tolerability, reduced or eliminated MC1R-mediated hyperpigmentation, and dosing characteristics suitable for chronic treatment.
Next-Generation Long-Acting Peptide MC4R Agonists
Palatin is advancing two complementary MC4R-selective peptide series: lipidated PL2000 and non-lipidated PL1000.
- The lead lipidated PL2000 development candidate has demonstrated significant reductions in food intake and body weight following once-weekly subcutaneous administration in a diet-induced obese mouse model.
- Preclinical pharmacokinetic findings support the potential for once-weekly or less frequent dosing in humans.
- Tested compounds from both peptide series have demonstrated potent MC4R agonist activity without acting as agonists at MC1R, supporting the Company's objective of substantially reducing or potentially eliminating hyperpigmentation associated with MC1R activation.
- IND-enabling studies and chemistry, manufacturing and controls ("CMC") activities are ongoing for the lead lipidated peptide candidate.
- Palatin is targeting initiation of a Phase 1 single-ascending-dose/multiple-ascending-dose ("SAD/MAD") clinical study in the first half of calendar 2027, with initial data targeted in the second half of 2027.
- The Company continues to advance its non-lipidated PL1000 peptide series, including controlled-release formulation development, as an additional approach to long-acting MC4R therapy.
Next-Generation Oral MC4R Agonists
Palatin is pursuing oral MC4R-selective therapies through its small-molecule development program and an additional oral peptide agonist approach.
The oral small-molecule program incorporates data and learnings from earlier development candidates, including PL7737, together with advanced medicinal chemistry, computational drug design, artificial intelligence and machine learning capabilities.
- Preclinical studies have identified next-generation oral small-molecule candidates with improved potency and MC4R selectivity relative to earlier compounds, together with favorable oral bioavailability.
- The program is designed to achieve meaningful efficacy with improved tolerability and minimal or no MC1R-mediated hyperpigmentation.
- Lead candidate selection and optimization activities are ongoing, with IND-enabling development targeted for the first half of calendar 2027.
- A Phase 1 SAD/MAD study is targeted to initiate in the second half of calendar 2027, with initial clinical data targeted in the first half of 2028.
- Palatin is also exploring an oral peptide agonist approach as an additional opportunity to expand its MC4R-selective therapeutic portfolio.
Partnering and Out-Licensing Programs
Retinal Diseases – Boehringer Ingelheim
Palatin continues to collaborate with Boehringer Ingelheim on proprietary melanocortin receptor-targeted compounds for retinal diseases, including diabetic retinopathy and diabetic macular edema. Palatin provides research and development support, with approved costs reimbursed by Boehringer Ingelheim.
The agreement provides for potential future development, regulatory and commercial milestone payments, as well as tiered royalties on net sales of licensed products, if commercialized.
Palatin recognized approximately
PL9643 – Dry Eye Disease
Palatin's exclusive sublicense agreement with Altanispac Labs covers PL9643 for the treatment of dry eye disease. Altanispac is responsible for future development and commercialization. Palatin remains eligible for additional payments and tiered royalties under the agreement.
Additional Development and Partnering Opportunities
Palatin continues to evaluate strategic partnering and out-licensing opportunities for its bremelanotide co-administration program in obesity, PL8177 or other novel MC1R agonist in ulcerative colitis and its melanocortin receptor agonist program for diabetic nephropathy.
These programs provide opportunities to advance additional assets through strategic collaborations while maintaining Palatin's primary development focus on next-generation MC4R therapies for rare obesity disorders.
Fiscal 2027 First Quarter Ended September 30, 2026 Financial Results Revenue
For the fiscal first quarter ended September 30, 2026, Palatin recognized approximately
Revenue for the current quarter was attributable to research and development services performed under the Boehringer Ingelheim collaboration. The prior-year period included upfront and milestone revenue associated with that agreement.
Research and Development Expenses
Research and development expenses were approximately
R&D spending directly related to the Company's MC4R obesity programs increased to approximately
General and Administrative Expenses
General and administrative expenses were approximately
Net Loss
Palatin reported a net loss of approximately
Cash Flows and Cash Position
Net cash used in operating activities was approximately
As of September 30, 2026, Palatin had cash and cash equivalents of approximately
The Company intends to pursue additional financing and strategic opportunities to support continued advancement of its development programs. Additional funding will be required to execute its planned development activities and fund operations. Accordingly, substantial doubt exists regarding the Company's ability to continue as a going concern for one year following issuance of its financial statements.
Conference Call and Webcast
Palatin will host a conference call and audio webcast on November 17, 2026, at 11:00 a.m. Eastern Time, to discuss its fiscal first-quarter financial results and provide an update on corporate and development activities.
To listen to the live conference call, dial 1-888-506-0062 (US) or 1-973-528-0011 (International), Participant Access Code: 336522. The audio webcast and replay can be accessed by logging on to the "Investor-Webcasts" section of Palatin's website at http://www.palatin.com. A telephone and audio webcast replay will be available one hour after the completion of the call. To access the telephone replay, dial 1-877-481-4010 (US) or 1-919-882-2331 (International), Replay Passcode 54837. The webcast and telephone replay will be available through December 1, 2026.
About Palatin Technologies
Palatin Technologies, Inc. is a biopharmaceutical company developing medicines targeting the melanocortin receptor system. Palatin's principal strategic development focus is advancing next-generation MC4R-selective agonists for rare neuroendocrine obesity disorders, including hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome. The Company is developing long-acting injectable peptide agonists, oral small-molecule agonists and an oral peptide agonist approach, with the objective of delivering differentiated efficacy, tolerability and dosing profiles suitable for long-term treatment. Palatin also utilizes collaborations, licensing arrangements and strategic partnerships to advance other melanocortin-based programs. For more information, visit www.palatin.com.
Forward-Looking Statements
Statements in this press release that are not historical facts, including statements regarding Palatin's product candidates, potential clinical benefits, efficacy, tolerability, receptor selectivity, dosing frequency, development programs, regulatory submissions, clinical trial initiation and results, collaborations, financing plans and future operations, are forward-looking statements within the meaning of applicable federal securities laws. These statements involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Such risks include the results of preclinical and clinical studies, regulatory decisions, manufacturing and development timelines, Palatin's ability to obtain sufficient financing, the performance of collaborators and licensees, competing therapies, market conditions and other risks described in Palatin's filings with the Securities and Exchange Commission. Palatin undertakes no obligation to update forward-looking statements except as required by law.
|
|
PALATIN TECHNOLOGIES, INC |
||||
|
|
and Subsidiary |
||||
|
|
Consolidated Statements of Operations |
||||
|
|
(unaudited) |
||||
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
||
|
|
|
2026 |
|
2025 |
|
|
|
|
|
|
|
|
|
|
REVENUES |
|
|
|
|
|
|
Collaboration and license |
$ 361,802 |
|
$ 8,847,550 |
|
|
|
|
|
|
|
|
|
|
OPERATING EXPENSES |
|
|
|
|
|
|
Research and development |
3,383,743 |
|
2,525,766 |
|
|
|
General and administrative |
2,080,414 |
|
1,660,731 |
|
|
|
Total operating expenses |
5,464,157 |
|
4,186,497 |
|
|
|
|
|
|
|
|
|
|
(Loss) Income from operations |
(5,102,355) |
|
4,661,053 |
|
|
|
|
|
|
|
|
|
|
OTHER INCOME (EXPENSE) |
|
|
|
|
|
|
Investment income |
46,534 |
|
18,483 |
|
|
|
Interest expense |
(1,690) |
|
(2,002) |
|
|
|
Total other (expense) income, net |
44,844 |
|
16,481 |
|
|
|
|
|
|
|
|
|
|
NET (LOSS) INCOME |
$ (5,057,511) |
|
$ 4,677,534 |
|
|
|
|
|
|
|
|
|
|
Basic net (loss) income per common share |
$ (1.29) |
|
$ 4.81 |
|
|
|
|
|
|
|
|
|
|
Diluted net (loss) income per common share |
$ (1.29) |
|
$ 4.26 |
|
|
|
|
|
|
|
|
|
|
Weighted average number of common shares |
3,922,464 |
|
971,650 |
|
|
|
|
|
|
|
|
|
|
Weighted average number of common shares |
3,922,464 |
|
1,098,490 |
|
|
|
PALATIN TECHNOLOGIES, INC |
|||
|
|
and Subsidiary |
|||
|
|
Consolidated Balance Sheets |
|||
|
|
(unaudited) |
|||
|
|
|
|
|
|
|
|
|
September 30, 2026 |
|
June 30, 2026 |
|
|
ASSETS |
|
|
|
|
|
Current assets: |
|
|
|
|
|
Cash and cash equivalents |
$ 3,740,424 |
|
$ 7,492,014 |
|
|
Accounts receivable |
361,802 |
|
300,770 |
|
|
Prepaid expenses and other current assets |
337,765 |
|
371,703 |
|
|
Total current assets |
4,439,991 |
|
8,164,487 |
|
|
|
|
|
|
|
|
Property and equipment, net |
101,112 |
|
118,064 |
|
|
Right-of-use assets - operating leases |
155,448 |
|
219,677 |
|
|
Other assets |
21,626 |
|
21,626 |
|
|
Total assets |
$ 4,718,177 |
|
$ 8,523,854 |
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
Accounts payable |
$ 1,360,530 |
|
$ 1,109,552 |
|
|
Accrued expenses |
1,171,975 |
|
504,158 |
|
|
Short-term operating lease liabilities |
126,661 |
|
158,263 |
|
|
Total current liabilities |
2,659,166 |
|
1,771,973 |
|
|
|
|
|
|
|
|
Long-term operating lease liabilities |
32,932 |
|
65,416 |
|
|
Total liabilities |
2,692,098 |
|
1,837,389 |
|
|
|
|
|
|
|
|
Stockholders' equity: |
|
|
|
|
|
Preferred stock of |
|
|
|
|
|
issued and outstanding designated as follows: |
|
|
|
|
|
Series A Convertible: authorized 4,030 shares as of September 30, 2026: issued |
|
|
|
|
|
and outstanding 4,030 shares as of September 30, 2026 and June 30, 2026 |
40 |
|
40 |
|
|
Series D Convertible: authorized 3,400 shares as of September 30, 2026: issued |
|
|
|
|
|
and outstanding 3,400 shares as of September 30, 2026 and June 30, 2026 |
34 |
|
34 |
|
|
Common stock of |
|
|
|
|
|
issued and outstanding 1,780,939 shares as of September 30, 2026 and 1,779,275 |
17,809 |
|
17,793 |
|
|
Additional paid-in capital |
474,517,501 |
|
474,120,392 |
|
|
Accumulated deficit |
(472,509,305) |
|
(467,451,794) |
|
|
Total stockholders' equity |
2,026,079 |
|
6,686,465 |
|
|
Total liabilities and stockholders' equity |
$ 4,718,177 |
|
$ 8,523,854 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BS Check |
$ - |
|
$ - |
|
|
Working Capital |
1,780,825 |
|
6,392,514 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-reports-fiscal-first-quarter-2027-financial-results-and-provides-business-update-302941645.html
SOURCE Palatin Technologies, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.